The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer
- PMID: 16634689
- DOI: 10.1517/13543784.15.5.507
The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer
Abstract
This review summarise the authors' recent experience in the development of antisense (AS) oligodeoxynucleotide (ODN) therapy that targets a cytoprotective gene, clusterin, for the treatment of prostate cancer. The acquisition of resistance to a wide variety of proapototic stimuli was initially demonstrated by introducing the clusterin gene into prostate cancer cells. Furthermore, silencing clusterin expression using AS ODN synergistically enhanced the effects of several conventional therapeutic modalities through the effective induction of apoptosis in prostate cancer xenograft models. Based on these outcomes, Phase I clinical trials were conducted using AS clusterin ODN incorporating 2'-O-(2-methoxy)ethyl-gapmer backbone (OGX-011), and the optimal dose of OGX-011 capable of inducing </= 90% suppression of clusterin in human prostate cancer tissue was determined. Collectively, these findings suggest the utility of inactivating clusterin function using AS ODN technology as a novel therapeutic strategy for prostate cancer treatment. There have been four kinds of Phase II studies that have begun to further evaluate the efficacy of OGX-011 in patients with prostate, breast and lung cancers.
Similar articles
-
Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.Int J Urol. 2005 Sep;12(9):785-94. doi: 10.1111/j.1442-2042.2005.01173.x. Int J Urol. 2005. PMID: 16201973 Review.
-
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.
-
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.Future Oncol. 2012 Oct;8(10):1239-51. doi: 10.2217/fon.12.129. Future Oncol. 2012. PMID: 23130925
-
Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.World J Urol. 2005 Feb;23(1):38-46. doi: 10.1007/s00345-004-0474-0. Epub 2005 Jan 26. World J Urol. 2005. PMID: 15770517 Review.
-
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.BJU Int. 2008 Aug;102(3):389-97. doi: 10.1111/j.1464-410X.2008.07618.x. Epub 2008 Mar 11. BJU Int. 2008. PMID: 18336596 Clinical Trial.
Cited by
-
Novel translational strategies in colorectal cancer research.World J Gastroenterol. 2007 Nov 28;13(44):5902-10. doi: 10.3748/wjg.v13.i44.5902. World J Gastroenterol. 2007. PMID: 17990355 Free PMC article. Review.
-
The evolving biology and treatment of prostate cancer.J Clin Invest. 2007 Sep;117(9):2351-61. doi: 10.1172/JCI31791. J Clin Invest. 2007. PMID: 17786228 Free PMC article.
-
Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?BMC Cancer. 2015 May 2;15:349. doi: 10.1186/s12885-015-1348-0. BMC Cancer. 2015. PMID: 25934174 Free PMC article.
-
Chemical modification: the key to clinical application of RNA interference?J Clin Invest. 2007 Dec;117(12):3615-22. doi: 10.1172/JCI33483. J Clin Invest. 2007. PMID: 18060019 Free PMC article. Review.
-
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR.PLoS One. 2008;3(10):e3617. doi: 10.1371/journal.pone.0003617. Epub 2008 Oct 31. PLoS One. 2008. PMID: 18974881 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
